Leuprolide (Leuprorelin / Lupron), Research Reference

Leuprolide (also known as leuprorelin; marketed as Lupron by AbbVie and under other brand names) is a synthetic GnRH (gonadotropin-releasing hormone) agonist with FDA approval across several clinical indications. It is a nonapeptide with a D-leucine substitution at position 6 and an ethylamide modification at the C-terminus, conferring greater receptor affinity and resistance to enzymatic degradation compared to native GnRH.

Leuprolide was first approved by the FDA in 1985 and remains one of the most widely used GnRH agonists in clinical medicine. Its clinical applications span oncology, gynaecology, and paediatric endocrinology. In the research peptide community, it is less commonly used than Gonadorelin or Triptorelin because its dominant clinical profile is suppressive, though limited research accounts describe short-course pulsatile use for HPTA stimulation.

Quick Reference

Overview

Leuprolide operates through the same pharmacological paradox that governs all potent GnRH agonists: initial agonist stimulation at GnRH receptors in the anterior pituitary raises LH and FSH output, but sustained stimulation causes receptor downregulation and desensitisation, ultimately suppressing LH and FSH and consequently reducing testosterone and oestrogen to near-castrate levels.

This mechanism is the basis for leuprolide’s primary clinical applications:

• Prostate cancer: Androgen deprivation therapy (ADT) using leuprolide is a cornerstone of treatment for locally advanced and metastatic androgen-sensitive prostate cancer. Testosterone suppression reduces androgenic stimulation of prostate cancer cells. Depot formulations provide months-long suppression from a single injection.
• Endometriosis: Oestrogen deprivation reduces endometrial lesion growth and associated pain. Research has reported improvements in pelvic pain, dysmenorrhoea, and dyspareunia with leuprolide in this context.
• Uterine fibroids: Research has investigated leuprolide for preoperative fibroid size reduction before myomectomy or hysterectomy, with oestrogen suppression driving fibroid regression.
• Central precocious puberty: Leuprolide is used to halt premature puberty by suppressing the gonadotropin stimulation that drives early pubertal development in children with CPP. Once treatment is discontinued, puberty resumes.
• Breast cancer: As an adjunct in premenopausal women with hormone receptor-positive breast cancer, leuprolide provides medical oophorectomy (oestrogen suppression) as part of combined hormonal management.

Research has also investigated leuprolide in fertility contexts (controlled ovarian stimulation protocols using GnRH agonist down-regulation) and in short-course HPTA restart research, though the latter represents a minority of community research accounts.

Mechanism

Leuprolide binds GnRH receptors on pituitary gonadotroph cells with higher affinity than native GnRH, driven by the D-Leu6 and ethylamide modifications that reduce enzymatic cleavage and increase receptor occupancy time.

Phase 1, Initial stimulation (approximately days 1–10): After the first injection, continued GnRH receptor stimulation drives a transient increase in LH and FSH secretion, and consequently an increase in testosterone in men or oestrogen in women. This is the testosterone/oestrogen flare that occurs with initiation of leuprolide therapy.

Phase 2, Receptor downregulation and suppression (from approximately 2–4 weeks with continuous use): Sustained GnRH receptor stimulation causes receptor internalisation and downregulation, progressively suppressing LH and FSH output. Testosterone in men typically falls below 50 ng/dL (castrate level) within 2 to 4 weeks and is maintained there for the duration of continuous therapy.

Critical distinction from Gonadorelin: The pulsatile use of Gonadorelin at twice-weekly or three-times-weekly intervals exploits the resensitisation window of GnRH receptors between pulses, preserving stimulatory LH and FSH output. Leuprolide’s longer half-life, depot formulations, and daily administration are specifically designed to prevent this resensitisation, achieving and maintaining suppression.

Approved Clinical Protocols (Reference)

The following reflects established clinical dosing reported in approved prescribing information and research literature. These are not research community protocols.

Prostate Cancer (ADT)

• Depot monthly (7.5 mg): Single intramuscular or subcutaneous injection every 28 days
• Depot 3-month (22.5 mg): Single injection every 12 weeks
• Depot 4-month (30 mg): Single injection every 16 weeks
• Depot 6-month (45 mg): Single injection every 24 weeks

Endometriosis and Uterine Fibroids

• Depot monthly (3.75 mg): Single intramuscular injection every 28 days, typically for 3–6 months; add-back therapy with low-dose oestrogen is commonly described to mitigate bone density effects
• Depot 3-month (11.25 mg): Single injection every 3 months

Short-Acting (Daily Subcutaneous)

• 1 mg per day: Once-daily subcutaneous injection; used in the short-acting form primarily in IVF down-regulation protocols or where flexibility in onset and duration is clinically preferred

Central Precocious Puberty

• Depot monthly: Doses adjusted by body weight, typically ranging from 7.5 mg to 15 mg per month in children with CPP

Research Community Context

In the research peptide community, leuprolide is considered less versatile than Gonadorelin or Triptorelin for non-oncology research contexts:

• Gonadorelin is used in TRT protocols to preserve pulsatile HPG axis function and prevent testicular atrophy during exogenous testosterone use. Its extremely short half-life (2–10 minutes) makes twice-weekly subcutaneous injection stimulatory rather than suppressive.
• Triptorelin has been investigated in short-course single-dose research protocols for HPTA restart, where a brief LH/FSH stimulus during the initial flare period before suppression occurs is the intended mechanism.
• Leuprolide in short-course HPTA research contexts faces the same pharmacological challenges as triptorelin: achieving stimulation before suppression takes hold requires precise timing and carries risk of inducing the suppressive phase that characterises its approved clinical use. Research accounts in this context are limited, and the depot formulations that make leuprolide convenient in oncology are counterproductive for any stimulatory application.

Reported Side Effects

Reported side effects in research and clinical accounts include the following. This list reflects leuprolide’s suppressive mechanism and does not constitute a comprehensive safety profile.

Storage and Handling

Short-Acting (Daily Injection)

• Refrigerator (2–8 degrees C): Required; do not freeze
• Multi-dose vials: Contain bacteriostatic preservatives; stable at room temperature for up to 30 days once opened, per prescribing information

Depot Formulations

• Microsphere depot: Store at or below 25 degrees C (77 degrees F); protect from heat and light
• Reconstitution: Mix just before injection; depot formulations are typically dual-chamber syringes pre-packaged with diluent; follow manufacturer instructions
• Do not use if the suspension appears to have aggregated or if the microspheres do not disperse on gentle mixing

Frequently Asked Questions

Why does continuous Leuprolide use suppress rather than stimulate testosterone? Leuprolide binds GnRH receptors with greater affinity and for longer than native GnRH. Under physiological conditions, pulsatile GnRH release allows receptor resensitisation between pulses. Continuous or daily leuprolide use prevents resensitisation, causing receptor internalisation and downregulation. After an initial flare lasting 1 to 2 weeks during which testosterone rises, LH and FSH output falls as receptors become progressively desensitised, driving testosterone to castrate levels within 2 to 4 weeks.

How does Leuprolide differ from Gonadorelin and Triptorelin? Gonadorelin has a 2 to 10 minute half-life; at twice-weekly doses, each injection produces a brief pulsatile stimulus that preserves LH and FSH output. Triptorelin has a ~3-hour half-life and is available in depot formulations; it uses the same suppressive mechanism as leuprolide. Leuprolide is also a ~3-hour half-life compound with daily and depot formulations, primarily used when sustained gonadotropin suppression is the clinical goal.

What is the testosterone flare with Leuprolide and how is it managed? The testosterone flare is a transient testosterone rise during the first 1 to 2 weeks of leuprolide initiation, before receptor downregulation takes effect. In prostate cancer, this is managed with short-course androgen receptor antagonists (flutamide, bicalutamide) during the flare period to block peripheral androgen action until suppression is established.

Is Leuprolide used in research community peptide protocols? Primarily in clinical oncology, gynaecology, and paediatric contexts rather than community research protocols. Limited research accounts describe short-course HPTA restart applications, but the research community more commonly uses Gonadorelin (for HPG axis maintenance during TRT) or Triptorelin (for short-course restart research) given their better-characterised profiles in non-oncology research contexts.

Related Pages

Goals: Testosterone and Hormonal Support · Fertility and Reproductive Health

Class: Reproductive Peptides and GnRH Agonists

Comparisons: Gonadorelin vs Triptorelin

Also see: Gonadorelin · Triptorelin · Kisspeptin

References and Further Reading

• Labrie F, et al. (1982). New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clinical and Investigative Medicine, 5(2-3), 267–275. PubMed
• Crawford ED, et al. (1989). A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New England Journal of Medicine, 321(7), 419–424. PubMed
• Lupron Depot (leuprolide acetate for depot suspension) US Prescribing Information. AbbVie Inc. Accessed via FDA label repository. FDA
• Schally AV, et al. (1973). Isolation and structure of the hypothalamic follicle stimulating hormone-releasing factor (FSH-RF). Biochemical and Biophysical Research Communications, 53(4), 1076–1083. PubMed
• Shapiro CL, et al. (2001). Effects of adjuvant chemotherapy and hormonal therapy on bone density in breast cancer patients. Clinical Breast Cancer, 2(4), 268–274. PubMed